Clinical Trial Update: A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

Amgen reports completion of a Phase 3 trial evaluating self-administered rocatinlimab in adolescents and adults with moderate-to-severe atopic dermatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Rocatinlimab (rocatinlimab)

Snippet

Sponsor: Amgen | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED